Aplidin PharmaMar.
Aplidin is a cell cycle inhibitor being developed by PharmaMar SA for the potential treatment of a variety of cancers, including non-Hodgkin's lymphoma (NHL), non-small-cell lung cancer (NSCLC), acute lymphoblastic leukemia (ALL), neuroendocrine, prostate, gastric and colorectal cancers [390131], [464778].
Yao
Lei
L
Experimental Transplantation and Immunology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA. Yaol@mail.nih.gov
D000818:Animals; D002453:Cell Cycle / Q000187:drug effects / Q000502:physiology; D002986:Clinical Trials as Topic / Q000706:statistics & numerical data; D047630:Depsipeptides; D006131:Growth Inhibitors / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy; D010456:Peptides, Cyclic / Q000737:chemistry* / Q000494:pharmacology / Q000627:therapeutic use*; D013678:Technology, Pharmaceutical / Q000331:legislation & jurisprudence / Q000379:methods*
D047630:Depsipeptides; D006131:Growth Inhibitors; D010456:Peptides, Cyclic; C098980:plitidepsin